🩸 Heme/Onc Fellow @UToledo | 🏛️ Former Harvard Faculty | 📝 #Frontiers Editor | 🛂 VP @ASCO-CoP Visa Advocacy | 🤖 AI in Medicine |Creator #HemeOncSimplified
Toledo, OH
Joined October 2011
- Tweets882
- Following535
- Followers1.3K
- Likes2.1K
🪔 Happy Diwali from Hemonc Simplified🥳! As diyas light up homes tonight, we celebrate the victory of light over darkness and good over evil. Wishing you and your family happiness, health, and bright new beginnings🫶🙏🏻 📸 instagram.com/hemoncsimplifi… #Diwali2026 #DiwaliCelebration
👋You asked and it’s here !!
Check out 007 CD Markers & Flow Simplified from Hemonc Simplified on Amazon Music👇👇, I Heart, Apple podcast and Spotify . music.amazon.com/podcasts/a8…
🔥ESMO2026🔥
🧬 Can personalized mRNA vaccines change cancer treatment?
Explore the INTerpath-001 trial and its promising findings in melanoma! 🔬
🎥 Watch now 👇
youtu.be/J9XLwJmicYo
#ESMO2026 #Oncology #Immunotherapy #HemeOncSimplified @IMG_Oncologists @HemOncFellows @ASCO
🩸 Why does G6PD deficiency cause hemolysis?
↓ G6PD → ↓ NADPH → oxidative stress → Heinz bodies + bite cells!
🧠 Board pearl: G6PD levels may appear normal during acute hemolysis. Repeat after recovery
#MedEd @ASCO #MedTwitter @IMG_Oncologists @HemOncFellows @realbowtiedoc
ESMO 2026 TOP 10
#HemoncSimplified
The ten most likely practice-changing headlines from the ESMO Congress 2026 (Madrid, October 23–27, 2026), ranked #1 to #10 — all late-breaking randomized Phase 3 readouts. Full numbers and citations below. Watch recap Insta👉@hemoncsimplified
A beautiful tribute to a truly inspiring soul. 🙏🏻❤️ She will forever live in our hearts and continue to inspire us. 🫶 Thank you, @NBCNews, for sharing these stories and honoring the lives and legacies of physicians who touch so many hearts. 🫶❤️! You tc and b strong@supriyadocc
This melts my heart. She sparked my love for oncology, and working with her and learning from her was a true blessing. We miss you. ❤️
Remembering Dr. Rachna Shroff, Trailblazer in Cancer Research youtu.be/JcU-Vd57Um0?is=sNRh…
Wonderful!! Thanks @ADesaiMD 👇👇👇
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
➡️ OS 21.1 vs 12.7 mo, HR 0.42
➡️ PFS 7.4 vs 1.9 mo, HR 0.34
➡️ CRS 49.6% (G3+ 0.4%)
Amazing to be part of this practice-changing study on the global steering committee!!
@LungCancerRx @OncoAlert @oncodaily
🔬 ONC SPOTLIGHT — Jemperli for MSI-H/dMMR rectal cancer:71% drug alone, cCR12 47% · Keytruda TMB-H approval ≥13 mut/Mb,ORR 36% Camrelizumab TNBC pCR 57.5%, anthracycline-free📸 instagram.com/hemoncsimplifi… #HemeOncSimplified @IMG_Oncologists @HemOncFellows @UToledo @ASCO @oncodaily
🔥 ESMO 2026 Presidential Symposium — topics to watch: INTerpath-001 · TroFuse-005 · KEYNOTE-C93 · Krascendo 1 · VOLGA · DeLLphi-305 · SAFFRON. Results next week — · IG &🎙️ @HemoncSimplified ·
@HemOncFellows @IMG_Oncologists @ASCO @myESMO
ONC SPOTLIGHT — Fri Oct 16: Anktiva+BCG → papillary-only bladder cancer (CR 62%) · Inluriyo+Verzenio for ESR1-mut breast (PFS 11.1 vs 5.5 mo) · Lyrfigtu for FGFR2 bile-duct cancer (ORR 46%) follow @hemonc_dr - Insta #HemoncSimplified - podcast and Youtube for more updates!!!
Definitely one for the bookmarks! 📌 A remarkable contribution to #MultipleMyeloma! Huge kudos to @VincentRK for your relentless efforts, dedication, and continued impact on the field! 👏🏻🙏🏻 #Myeloma #MyelomaResearch
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
Dr. Schroff’s legacy lives🤍 on! Thank you, 🙌🏻NBC News, for the wonderful coverage! 👌🏻🙏🏻
Leading Cancer Researcher, 47, Dies of the Disease She Was Trying to Cure. This Was Her 1st Symptom nbcnews.com/health/disease/r… via @nbcnews
Such a tremendous loss to the GI Onc community!! 💔 Your courage, infectious smile, positivity, and unwavering dedication will forever inspire us. May you rest in eternal peace. Praying God grants your family strength and peace during this difficult time. 🤍🤍🤍🙏🏻@rachnatshroff
Devastating news 💔
Rest in peace dear Rachna.
medicine.arizona.edu/news/20…
🎯🤩 Excited to launch weekly news
🔬 ONC SPOTLIGHT
🧬 Adjuvant atezo in dMMR colon: HR 0.50
🎗️ Tucatinib maintenance in HER2+ mBC: PFS 24.9 vs 16.3 mo
💊 Camizestrant + CDK4/6i in ESR1m: PFS 16 vs 9.2 mo
🔬 Belzutifan + lenvatinib in RCC post-IO: PFS 14.6 vs 10.6 mo
Good to remember
And then in September 2026: we got 5 more new drugs/indications ✅ @FDADrugs!! As a #CommunityOncologists, we need to know them all:
1. #Camizestrant in mESR1 HR+ breast cancer (before progression). ⬆️mPFS (16mos vs. 9.2mos)
2. #Imlunestrant + #Abemaciclib in 2L metastatic mESR1 HR+ breast cancer. ⬆️mPFS (11.1mos vs. 5.5mos)
3. #Sevabertinib now in 1L Her2 mutated NSCLC. ORR 75%
4. #Lirafugratinib in 2L for FGFR2 fusion/rearrangement cholangiocarcinoma. ORR 46% and DoR 11.8mos
5. #Belzutifan + #Lenvatinib in 2L RCC. ⬆️mPFS (14.6mos vs. 10.6mos)
#OncTwitter #bcsm #lcsm #gusm @OncUpdates @FDA @US_FDA
Excellent to keep a note !!
Three things I recommend for using Bispecific antibodies in myeloma:
1) Prophylactic tocilizumab with first dose
2) Monthly IVIG regardless of the IgG level
3) Consider reducing frequency/stopping after excellent response.
This applies to all the approved bispecifics: teclistamab, elranatamab, linvoseltamab, and talquetamab.
Academic centers with expertise and close monitoring capabilities may skip the prophylactic tocilizumab but in general I do not see community adoption without it.
The data on routine IVIG and early use before the IgG levels drop or infections occur is good and sufficient to move forward. It’s recommended in NCCN and mSMART. Bispecifics are better at controlling myeloma than standard triplets and quads, but pose a much higher risk of serious life threatening infections without prophylaxis and careful adjustment of dosing schedule based on response and patient characteristics.
#IMS26